PNT News and Press, POINT Biopharma Global Inc. From 06/12/23

INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the filling of its vacant b...

Register online today at: https://hub.pointbiopharma.com/investor-day-june-2023 INDIANAPOLIS, June 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and gl...

NORTHAMPTON, MA / ACCESSWIRE / May 30, 2023 / Pentair Originally published on GreenBiz.com by Karla Robertson, Executive Vice President, General Counsel, Secretary, and Chief Social Responsibility Officer As we emerge from the pandemic, one outcome is the increased value placed by employees...

PNT2004 program’s phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25 th Poster to be available starting at 9:00 AM ET, June 3 rd INDIANAPOLIS, May 25, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc....

2023-05-19 10:27:15 ET Summary The company's innovative product pipeline and exclusive CanSEEK technology offer groundbreaking cancer treatments that address unmet clinical needs, positioning POINT for leadership in the biopharma industry. POINT Biopharma recently received FDA Fas...

2023-05-15 14:53:32 ET Shares of Point Biopharma Global (NASDAQ: PNT) were up 11.4% Monday afternoon after the healthcare company reported its first-quarter earnings and made an announcement about a collaboration with a manufacturer. The stock is up more than 46% so far this yea...

2023-05-15 09:46:44 ET POINT Biopharma Global press release ( NASDAQ: PNT ): Q1 GAAP EPS of -$0.16 beats by $0.15 . As of March 31, 2023, POINT had approximately $519.2 million in cash, cash equivalents, and investments, which is anticipated to fund operations into 202...

INDIANAPOLIS and LANSING, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and IONETIX Corporation (...

U.S. FDA granted Fast Track designation for 177 Lu-PNT2002 for the treatment of mCRPC in April 2023 Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer, Ionetix Alpha Corp. INDIANAPOLIS, May 15, 2023 (GLOBE NEWSWIRE) -- PO...

NORTHAMPTON, MA / ACCESSWIRE / May 4, 2023 / Pentair Karla Robertson highlighted the positive impacts made in 2022 during Pentair's Global Town Hall in May 2023. As published on the Pentair Blog By Karla Robertson, Pentair Executive Vice President, General Counsel, Secretary, and Chief...